Jaguar Health, Inc. filings document a commercial-stage pharmaceutical issuer with Nasdaq-listed common stock and a focus on plant-derived gastrointestinal medicines. Recent 8-K reports cover Nasdaq continued-listing standards, bid-price and publicly held share requirements, reverse-stock-split effects, pre-funded warrant exercises, stockholders' equity considerations, and material agreements involving Napo Pharmaceuticals.
Proxy and charter filings describe stockholder votes, amendments to the company's certificate of incorporation, authorized-share changes, and governance procedures. The company's regulatory record also includes disclosures on crofelemer programs, Mytesi, Canalevia-CA1, operating and financial results, capital structure, clinical or regulatory matters, and other material events affecting the human-health and animal-health businesses.
Jaguar Health, Inc. (JAGX) is registering a shelf of securities with an aggregate public offering price of $75,000,000, including $41,559,118.01 in aggregate maximum offering price of unsold securities carried forward from an earlier registration. Jaguar may sell common stock, preferred stock, warrants, subscription rights or units from time to time; each sale will have specific terms in a prospectus supplement and may occur only after the registration statement is effective. Jaguar intends to use net proceeds for working capital and general corporate purposes, and possibly to pursue other strategic alternatives.
Following a January 2026 U.S. licensing agreement between Napo and an affiliate of Future Pak, Future Pak became exclusive marketer for Mytesi and Canalevia-CA1. Jaguar was provided with $16.0 million of non-dilutive capital, with $2.0 million due upon completion of post-closing conditions and up to $20 million in milestone and other future payments. OnTarget did not meet its primary endpoint across all tumor types and targeted therapies; its prespecified breast cancer subgroup showed statistically significant improvement in monthly responder analysis.
Jaguar Health, Inc. (JAGX) is asking stockholders at its November 6, 2026 special meeting to approve six proposals: issuance of common shares upon exchange of Series Q preferred stock and CVP debt; repricing investor warrants; expanding the 2014 Stock Incentive Plan; authorizing a reverse split; reducing the ELOC Agreement’s Floor Price; and possible meeting adjournments.
In an illustrative full exchange at the September 25, 2026 Minimum Price of $7.06, 899.82 Series Q shares and approximately $2,895,351 of CVP Debt would convert into 3,596,425 common shares, approximately 64.9% of shares after the exchange. Approval would permit exchanges without another stockholder vote, after required amendments remove specified ownership caps.
The warrant proposal would reduce exercise prices from $525.00–$3,996.60 to $1.00 per share. Upon exercise, holders would be entitled to up to 45,511 Series O shares and are expected to be entitled to up to 20,260 Series R shares, assuming the warrants remain outstanding on the Series R Record Date. Other proposals would authorize 378,859 plan shares, representing 14% of fully diluted shares as of September 30, 2026; let the board set a 1-for-2 to 1-for-150 reverse-split ratio if approved; and lower the ELOC Floor Price from $16.50 to $1.10 per share.
Jaguar Health, Inc. declared a special dividend of one Series R Convertible Preferred share per common share held at the close of business October 13, 2026, and per share issuable under eligible warrants covering up to 142,535 common shares. Payment is scheduled for October 15, 2026. Each Series R share converts automatically on November 2, 2026 into five common shares, subject to a 19.99% beneficial-ownership cap; the aggregate conversion-share limit is 11,625,000, subject to adjustments.
Monthly payments under each $12 million original-principal royalty interest with Uptown Capital and Streeterville Capital are scheduled to begin January 1, 2027, instead of October 1, 2026; each payment is the greater of $750,000.00 or the royalty amount due under its agreement. The maturity of the 2021 secured note, originally $6,220,812.50, was extended from October 1, 2026 to January 1, 2027.
Jaguar warns conversion may significantly dilute holders not entitled to the dividend, depress the common-stock price and make additional equity financing more difficult. Conversion shares that would breach a holder’s 19.99% beneficial-ownership cap are held in abeyance. C/M Capital consented to the dividend and Series R authorization; Jaguar agreed to repurchase all Series P shares then held by C/M Capital for cash at the applicable liquidation amount upon a Fundamental Transaction, subject to legally available funds and required approvals.
Jaguar Health, Inc. (JAGX) amended and restated its preliminary proxy for a special meeting scheduled for November 6, 2026, changing the meeting date, revising Proposal 1 and stating that Proposal 6 is removed. The explanatory note says Proposal 6 is removed, although the included notice and proxy text still list and describe it.
Stockholders are asked to approve potential common-share exchanges of Series Q preferred stock and CVP debt. In an illustrative full exchange at a $7.06 Minimum Price as of September 25, 2026, 3,596,425 shares could be issued, or approximately 64.9% of common shares after issuance. Other proposals would reprice warrants to $1 per share, with up to 49,690 shares potentially issuable assuming cash exercise and exercise of related placement-agent warrants; increase the 2014 Plan authorization to 14% of fully diluted shares; and permit a reverse split from 1-for-2 to 1-for-150, with the board setting the ratio if approved. Stockholders are also asked to approve a reduction to the ELOC Agreement’s Floor Price.
Jaguar Health, Inc. (JAGX) issued 481,584 common shares to Streeterville Capital, LLC under privately negotiated exchange agreements in exchange for a $3,400,000 reduction in the outstanding balance of the company’s 2021 secured promissory note. The note was issued January 19, 2021, with original principal of $6,220,812.50. Jaguar reported approximately 1,945,542 common shares issued and outstanding as of September 25, 2026.
Jaguar Health, Inc. (JAGX) common stock is the subject of Amendment No. 1 to Schedule 13G, in which Joshua Mailman reports beneficial ownership of 189,617 shares, or 9.99% of the class. He reports sole voting and dispositive power over 186,205 shares and shared voting and dispositive power over 3,412 shares.
On September 23, 2026, Jaguar Health, Inc. (JAGX) issued 182,091 common shares to Streeterville Capital, LLC in exchange for a $1,678,320 reduction in the outstanding balance of its 2021 secured promissory note. That note had an original principal amount of $6,220,812.50.
Jaguar Health also issued 547,898 common shares to Streeterville in exchange for a $5,049,909.26 reduction in the outstanding balance of its 2025 secured promissory note, which was fully paid and cancelled upon completion of the exchange. The 2025 note had an original principal amount of $10,810,000. Jaguar Health reported approximately 1,463,958 common shares issued and outstanding as of September 24, 2026.
Jaguar Health, Inc. may sell shares of common stock through its at-the-market program for an aggregate offering price of approximately $9,824,188. That amount reflects Form S-3 limits and sales to date; approximately $4,899,873 in shares had been sold under the applicable limit during the prior 12-month calendar period ending September 24, 2026.
Ladenburg Thalmann & Co. is the sole sales agent as of January 1, 2026, after Lucid Capital Markets’ term expired December 31, 2025. The company’s stated non-affiliate market-value calculation was approximately $44,172,183 as of September 23, 2026, based on 1,281,839 outstanding shares held by non-affiliates at $34.46 per share, the September 22, 2026 closing price. Common stock last sold for $8.91 per share on Nasdaq on September 23, 2026.
Jaguar Health, Inc. (JAGX) issued 547,898 shares of common stock to Streeterville Capital, LLC in exchange for a $5,049,909.26 reduction in the outstanding balance of the 2025 Note. The exchange agreements were privately negotiated and entered into on September 23, 2026.
The 2025 Note had an original principal amount of $10,810,000 when issued on November 12, 2025. Jaguar stated that the exchange shares were issued in reliance on a Securities Act registration exemption. The company had approximately 1,281,867 shares of common stock issued and outstanding as of September 23, 2026.
Jaguar Health, Inc. (JAGX) reported changes to its capital structure. On September 15, 2026 the company filed a Certificate of Elimination in Delaware that removed the terms of multiple specified series of preferred stock from its Third Amended and Restated Certificate of Incorporation and returned those shares to authorized but undesignated preferred stock. All shares of these preferred series had already been converted, exchanged or otherwise disposed of before that date, and no such shares were outstanding immediately before the filing. As previously disclosed, on September 17, 2026 the company effected a 1-for-15 reverse stock split of its common stock, after which it had approximately 520,088 shares of common stock outstanding.